Merck scores another win for Keytruda, this time in HER2-negative cancer

Merck’s anti-PD1 oncology megablockbuster Keytruda is planning on adding another indication to its array, touting a Phase III win in its march to regulators.

Merck put out word Tuesday that one of its Phase III trials, KEYNOTE-859, nailed the primary endpoint of overall survival in patients with a specific type of HER2-negative adenocarcinoma.